NCT06354868View on ClinicalTrials.gov

A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy

Not yet recruitingOBSERVATIONAL

Enrollment

158

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Epilepsy

Sponsors

Lead Sponsor

Neuronostics Ltd

All Listed Sponsors

collaborator

Cornwall Partnership NHS Foundation Trust

NETWORK

lead

Neuronostics Ltd

INDUSTRY

NCT06354868 - A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy | Biotech Hunter | Biotech Hunter